FDA diagnostics guidance
This article was originally published in The Gray Sheet
Executive Summary
Agency issues guidance on statistically appropriate practices for reporting qualitative results from studies to assess diagnostic tests. The March 13 document, "Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests," makes recommendations for submitting 510(k)s and PMAs for diagnostics. The guidance covers results from different types of studies and describes best practices for data collection and analysis. The guidance also outlines common inappropriate practices, focusing special attention on discrepant resolution and its associated problems. The agency received 11 comments on the 2003 draft version (1"The Gray Sheet" March 17, 2003, p. 11)...
You may also be interested in...
New FDA Policy On Diagnostics Studies “Fills A Big Gap,” CDRH Chief Says
Companies specializing in diagnostic products should pay close attention to a new, statistics-focused guidance document from FDA, device center Director Dan Schultz says
IVD Study Designs Warrant Consultation With CDRH Staff – Draft Guidance
Discrepant resolution alone is an inadequate method for reliably estimating the value of a new diagnostic test in relation to an imperfect standard, an FDA draft guidance states
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.